Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.68 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.68 |
| ▸ | CHRNG | P07510 | 4/20 | 0.68 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.68 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.68 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.68 |
| ▸ | CHRND | Q07001 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.68 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686427 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL35211 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| Hydrochloric Acid SCHEMBL12497918 | 0.99 | SLC6A2 (0.68) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL770048 | 0.89 | SLC6A2 (0.68) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL769847 | 0.86 | SLC6A2 (0.64) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL4874443 | 0.86 | SLC6A2 (0.64) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL13151517 | 0.86 | SLC6A2 (0.68) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL634045 | 0.84 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL769133 | 0.84 | SLC6A2 (0.61) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 | |
| SCHEMBL633272 | 0.83 | SLC6A2 (0.60) | SLC6A2SLC6A3CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660274-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | AXSOME THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | claimed |
| US-20220249406-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-08-11 | — | — | US | claimed |
| US-11331285-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | AXSOME THERAPEUTICS, INC. (US) | 2022-05-17 | — | — | US | claimed |
| EP-3755312-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Axsome Therapeutics, Inc. (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200222339-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2020-07-16 | — | — | US | claimed |
| US-20200222342-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2020-07-16 | — | — | US | claimed |
| US-20200093760-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2020-03-26 | — | — | US | claimed |
| WO-2020061486-A2 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| WO-2019165379-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. (US) | 2019-08-29 | — | — | WO | claimed |
| US-20190216801-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | AXSOME THERAPEUTICS, INC. | 2019-07-18 | — | — | US | claimed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | claimed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | claimed |
| JP-2004513061-A | — | — | 2004-04-30 | — | — | JP | claimed |
| EP-1259243-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR, INC. (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020052340-A1 | Bupropion metabolites and methods of their synthesis and use | JERUSSI THOMAS P (US) | 2002-05-02 | — | — | US | claimed |
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | SEPRACOR INC. | 2002-05-02 | — | — | US | claimed |
| US-6342496-B1 | BRAIN DISORDERS | SEPRACOR INC. | 2002-01-29 | — | — | US | claimed |
| EP-1165086-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | Sepracor Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2001062257-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2001-08-30 | — | — | WO | claimed |
| WO-2000051546-A2 | BUPROPION METABOLITES AND METHODS OF THEIR SYNTHESIS AND USE | SEPRACOR INC. (US) | 2000-09-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052341-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A2 6/4885SLC6A3 10/4885CHRNA1 86/4885 |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | SLC6A2 11/4885SLC6A3 35/4885CHRNA1 74/4885 |
| US-20200093760-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
| US-20220249406-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
| US-20200222342-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
| US-20200222339-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
| US-11331285-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
| US-20190216801-A1 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | CYP2D6, DBH, CYP3A43 | SLC6A2 31/4885SLC6A3 21/4885CHRNA1 246/4885 |
| US-20020052340-A1 | Bupropion metabolites and methods of their synthesis and use | MAOB, MAOA, HTR5A | SLC6A2 4/4885SLC6A3 11/4885CHRNA1 76/4885 |
| US-11660274-B2 | Dosage forms and methods for enantiomerically enriched or pure bupropion | CYP2D6, CYP3A5, CYP2B6 | SLC6A2 7/4885SLC6A3 12/4885CHRNA1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.